Data assessments help payers analyze the quality and completeness of their patient clinical data necessary to identify and provide care for specific chronic disease states that render their members vulnerable to COVID-19.Verinovum’s chronic condition data assessment helps payers assess the quality of their clinical data for specific conditions and pinpoint exactly which data elements are needed for each member cohort.

The assessment involves two phases: within 60 days of receiving raw clinical data, Verinovum delivers a high-level report identifying gaps in overall data completeness. Then, 30 days thereafter, Verinovum highlights areas where significant data enrichment improvements are possible for specific chronic disease use cases such as asthma or diabetes, including medications, diagnosis, procedures, lab results, vital signs, and more.

As an example of how Verinovum helps improve data quality, in a recent engagement with a major national health plan, only 14% of the raw clinical data had the proper structure and requisite data elements to support advanced clinical and analytical use cases. After Verinovum curated and enriched the data, more than 89% was usable, directly impacting patient outcomes and dramatically improving data integrity for use with downstream applications.

Payers need to accurately identify their most at-risk populations by integrating, cleansing and enriching clinical data in order identify and serve their most vulnerable chronically ill members.